SOT FDA Colloquia on Emerging Toxicological Science: Challenges in Food and Ingredient Safety
The Toxicology of Nanoparticles
April 8, 2021 • Live Webcast • 9:00 AM–12:40 PM Eastern US, UTC-4
Chair: Rick Canady, NeutralScience
Co-Chair: Kapal Dewan, US FDA CFSAN
The Society of Toxicology in conjunction with the US FDA Center for Food Safety and Applied Nutrition (CFSAN) have partnered to provide this colloquia series. The colloquia present scientific information that is high-quality, cutting-edge, future-oriented toxicological science to provide a well-grounded foundation to inform the work of US FDA employees. These webcasts are open to the public at no charge. These sessions are not a public forum for discussion of toxicology regulatory issues.Webcast Registration
One of the most challenging aspects of safety assessment for nanomaterial use in consumer products is deriving an estimate of dose from use of a product that can be compared to doses delivered in a toxicology assay. What is the status of this critical translation between use and testing today? This SOT FDA Colloquium will explore issues of problem formulation for toxicology and exposure assessment in safety assessment of nanomaterial use in consumer products.
During the presentations, consider these questions posed by the two panelists which will be discussed during the roundtable discussion.
Agnes G. Oomen, PhD
National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
- Should well-dispersed nanomaterials be used for toxicity testing to cover worstcase exposure situations?
- How should we interpret toxicity studies in which there was some degree ofagglomeration?
- To which extent is information on toxicokinetics, e.g., internal exposure, needed to aid understanding the relationship between external exposure and hazard?
Timothy V. Duncan, PhD
US FDA, Bedford Park, IL
- What are the key challenges that nano introduces to comparison of acceptable intakeestimates to measured intake estimates?
- What recommendations would you give for standardizing operational procedures todetermine and report critical nano-toxicological and nano-exposure data?
- Should the approach to safety assessment differ when a nanomaterial isintentionally added to a food vs. indirectly or unintentionally present?
- Because key metrics like dose, identity, etc., are much more complicated for nanomaterials across concentrations and local conditions, should procedures be changed to ensure that allowable limits have enough of a safety margin?
|9:00 AM–9:05 AM||
|9:05 AM–9:10 AM||
Overview and Speaker Introductions
|9:10 AM–9:45 AM||
Lessons Learned from Nanomaterial Characterization: Critical Quality Attributes that Influence Biological Properties
|9:45 AM–10:20 AM||
Standard Dose Measurement for Nanomaterials: What to Include in Exposure and Toxicity so That We Can Bound Dose Estimates for Safety?
|10:20 AM–10:30 AM||
|10:30 AM–11:05 AM||
Dosing-Related Challenges in Toxicity Studies and Risk Assessment of Titanium Dioxide in Food
|11:05 AM–11:40 AM||
Practical Application to Regulatory Toxicology: Issues Faced in Consideration of Developing Health Guideline Values
|11:40 AM–12:40 PM||Roundtable Discussion
Moderators: Rick Canady, NeutralScience LC3, Camano Island, WA
Timothy Duncan, US FDA, Bedford, IL
Agnes Oomen, RIVM, Bilthoven, Netherlands
Please note that the WebEx service used allows audio and other information sent during the session to be recorded. By registering for this session, you automatically consent to such recordings. The recording of the event is posted to the SOT website for public access after the event. If you do not consent to being recorded, discuss your concerns with the host or do not join the session.
For registration questions contact Jim Dailey.
Richard Canady, PhD; Colloquium ChairRichard Canady has served in senior science policy roles for human health risk assessment for the White House, US Food and Drug Administration, and the Centers for Disease Control as well as for consulting and nonprofit corporations for a variety of government and industry clients in the US and Europe. Particular interests are health promotion, safe development of novel technology, and balancing bias across stakeholder perspectives. Dr. Canady received a PhD in neurophysiology and behavior from the Rockefeller University and maintained certification from the American Board of Toxicology (DABT) for 15 years.
Kapal Dewan, MS, CLSp(CG), Co-Chair
Kapal Dewan has 30 years of experience in regulatory science, toxicology, and clinical genetics. She has worked as a scientist at companies such as DuPont Bristol-Myers Squibb and Merck in the R&D Department. She has a dual career, having worked as a clinical geneticist with Christiana Health Care Systems for 10 years. Since 2008, she has been in the Office of Cosmetics and Colors (OCAC) at the US Food and Drug Administration (FDA). Currently, she is a team lead and oversees compliance-related activities for cosmetics to ensure that cosmetic products marketed in the US comply with the FDA laws and regulations. Mrs. Dewan leads a team of scientists comprising microbiologists, regulators, chemists, and biologists who are actively involved in scientific review of data to support regulatory decisions and policy development for cosmetic products. She is also actively involved in the FDA’s Marijuana Working Group and Nanotechnology Task Force activities. Mrs. Dewan plays a key role in coordinating and leading cosmetics related activities at OCAC. She is the lead author of the cosmetics nanotechnology guidance “Safety of Nanomaterials in Cosmetics.” She has presented at scientific and regulatory meetings and published several scientific papers in peer reviewed journals. Mrs. Dewan has a MS in Biology with an emphasis in genetics and a BS in Biology from the Science College, University of Patna, Patna, Bihar, India. She is a recipient of the prestigious gold medal for standing first class in order of merit in the MS (1983). She conducted three years of post-graduate research in genetics at Delhi University .
Anil Patri, PhD
Anil Patri serves as the Chair, Nanotechnology Task Force, and Director of Nanocore, National Center for Toxicological Research, US Food and Drug Administration. His laboratory is very active in regulatory science research to understand material characteristics and safety and efficacy of products containing nanomaterial, and provides training to scientists and reviewers at FDA. He serves on the US National Nanotechnology Initiative Nanoscale Science, Engineering, Technology Subcommittee and Nanotechnology and Environmental Health Implications working group for interagency coordination. Dr. Patri is as member of ISO TC229 and serves on the executive committee of ASTM E56 to facilitate standards development in nanotechnology. He co-chairs the EU-US Nanomedicine and Characterization Communities of Research.
Prior to joining FDA in 2014, Dr. Patri served as the Deputy Director, Nanotechnology Characterization Laboratory (NCL), at the National Cancer Institute. In a decade-long tenure at NCL, he assisted collaborators from industry and academia towards clinical translation of drug products utilizing nanotechnology. From 2006-2014, he also served as a guest scientist at the National Institute of Standards and Technology. Dr. Patri developed nanotechnology-based targeted drug delivery and imaging agents for cancer until 2004 at the Center for Biologic Nanotechnology, University of Michigan Medical School. He obtained his PhD from the University of South Florida, conducting basic research on dendritic nanomaterial. Dr. Patri is a principal investigator on several ongoing research projects and a co-author of over 70 peer reviewed publications.
Christie Sayes, PhD
Christie Sayes is a practicing research scientist in the fields of toxicology, chemistry, material science, and environmental health. Currently, she holds the position of Associate Professor of Environmental Science and Toxicology at Baylor University. Sayes is a subject matter expert in advanced materials, human exposure and health effects, and risk science. Her activities include working with partners, collaborators, and trainees in designing studies related to safety-by-design considerations of engineered materials used in drug delivery and consumer product applications. Dr. Sayes is also interested in occupational safety and environmental transformations of particle systems in complex matrices. She possesses a working knowledge of laboratory science and US regulatory climates. Routine activities include cell culture, zebrafish and rat in vivo models, biomolecular mechanistic analyses, mass spectrometry, electron microscopy (TEM and SEM), and statistics. Data sets are always related back to the published literature, compared against appropriate controls, and verified using orthogonal methods.
Christie received her PhD in Chemistry in 2005 from Rice University. Her dissertation focused on the “nano-bio interface.” After graduation, she joined The DuPont Company as Visiting Scientist and aided in the development of the DuPont-Environmental Defense Nano Risk Framework, the international standard for assessing risks associated with engineered nanomaterials .
Walter Brand, PhD
Dr. Walter Brand is a toxicologist and works as a scientific officer at the National Institute for Public Health and the Environment (RIVM) in The Netherlands. Main topics of his current work concern the risk assessment of the application of nanomaterials in food, the safety of chemical substances in consumer products, and children-specific issues related to exposure. He has a master’s in human nutrition and health and did his PhD in toxicology at Wageningen University, the Netherlands. He has a broad background in various fields and aspects of toxicology, as he previously worked as a risk assessor regarding human toxicology of pesticides, as a postdoctoral researcher in the implementation of bioassays in chemical water safety, and as a trainee study director and scientist in pharma R&D. Within this broad range of experience in the life sciences, he has a proven track record with various scientific publications and reports.
Lynne Haber, PhD
Lynne Haber is an Associate Professor in the Department of Environmental and Public Health Sciences at the University of Cincinnati, where she leads the Risk Science Center within the department. She received her PhD in molecular biology from the Massachusetts Institute of Technology. She coauthored hundreds of documents for multiple federal and state/provincial agencies and private sponsors, including assessments of several nanomaterials for the Consumer Product Safety Commission. Her risk assessment methods research has included improving methods for extrapolating from the available data to safe exposures and designing approaches to address challenging risk assessment questions. For example, Dr. Haber has investigated the use of biomarkers in risk assessment and is currently working on improvements to read-across and other methods for data-poor chemicals. She has served on peer review panels for EPA and other US and foreign government agencies, as well as private organizations; on two panels for the NAS/NRC; and on the IPCS EHC 240 dose-response author group. She has authored/coauthored more than 50 publications of chemical assessments or risk assessment methods, and more than ten book chapters, including as the lead author for the chapter on noncancer risk assessment in Patty’s Toxicology. She is also active in teaching continuing education courses. Dr. Haber has been a member of SOT since 1998 and has served as the Secretary/Treasurer of the Risk Assessment Specialty Section. She is a councilor in the Sustainable Chemicals through Contemporary Toxicology Specialty Section.
Timothy Duncan, PhD
Timothy Duncan received his undergraduate degree in chemistry in 2000 from Haverford College, located just outside of Philadelphia. He obtained his PhD in physical/inorganic chemistry in 2006 from the University of Pennsylvania under Professor Michael J. Therien (now at Duke University). The dissertation research involved measuring the photophysical properties of conjugated porphyrin arrays designed for medical diagnostic and optoelectronic applications. After graduation, his postdoctoral research was at the University of Pennsylvania in the lab of Professor So-Jung Park, where he built a single-molecule fluorescence imaging system to study the light emission properties of novel quantum-dot based bio-imaging agents and devised a new method to synthesize color-tunable conducting polymers. Since 2009 Dr. Duncan has been a research scientist at the US Food and Drug Administration’s Division of Food Processing Science and Technology. Current research interests include assessing exposure to nanomaterials from food contact materials and developing nanotechnology-enabled sensors for food safety.
Dr. Duncan has technical expertise in spectroscopy (including UV/Vis, fluorescence, infrared, time-resolved, nuclear magnetic resonance, and inductively-coupled plasma atomic emission), confocal and single-molecular microscopy, molecular photophysics, materials chemistry, thermal and mechanical analysis (including thermogravimetry, calorimetry, materials testing), nanomaterials, and polymer science. He also has formal training in risk management and food/drug law, and significant experience with data analysis, project management, technical writing, public speaking, and mentoring/teaching
Agnes Oomen, PhD
Agnes Oomen is a senior scientist at the National Institute for Public Health and the Environment (RIVM) in the Netherlands. She works at the interface between science and policy, leading and participating in national and European projects, for example, the health risks, toxicokinetics, grouping, and read-across of nanomaterials, as well as of other substances. She is an active member of the EFSA cross-cutting Working Group on Nanotechnologies and the EFSA Working Group on the food additive E171 (titanium dioxide). Dr. Oomen acts as an ad hoc expert in several international expert, working, and network groups. She is involved in the adaptation of OECD Test Guidelines and Guidance Documents on toxicokinetics to accommodate testing of (nano)particles. In addition, Dr. Oomen is exploring the topic of advanced materials in an international setting, taking into account issues related to their safety and sustainability by design, the scale of developments, and considering potential effects and the applicability of legal frameworks.
National Nanotechnology Initiative Public NanoEHS Webinar
March 23, 2021, 12-1:15 PM Eastern To register, please visit: NanoEHS Webinar Series
The 2021 NanoEHS webinar series will focus on sharing what we now know about the environmental, health, and safety aspects of engineered nanomaterials. Throughout the series, experts will share the big take-home EHS messages with the broader nanotechnology community and highlight the NNI's role in answering those questions. This webinar will feature experts from diverse disciplines to share their perspectives on key findings in quantifying and assessing the effects of human exposure to nanomaterials.
- Jia-Sheng Wang, MD, PhD, Colloquium Series Chair, University of Georgia, Athens, GA
- Udayan M. Apte, PhD, DABT, Colloquium Series Co-chair, University of Kansas Medical Center, Kansas City, KS
- Jason L. Aungst, PhD, FDA Liaison, US FDA, College Park, MD
- Stephen W. Edwards, PhD, RTI International, Chapel Hill, NC
- Suzanne Compton Fitzpatrick, PhD, DABT, US FDA, College Park, MD
- A. Wallace Hayes, PhD, DABT, ERT, ATS, FRSB, FACFE, University of South Florida and Michigan State University, Temple Terrace, FL
- Stephen M. Roberts, PhD, University of Florida, Gainesville, FL
- Jason Dietz, MS, Colloquium Chair, US FDA CFSAN, College Park, MD
- Alison Harrill, PhD, Council Contact, National Toxicology Program, Durham, NC
- Betty Eidemiller, PhD, SOT Staff, Reston, VA